Table 1 Baseline demographic and clinicopathologic characteristics for primary bladder SRCC (n, %)
Variable | Overall set | Training set | Validation set |
|---|---|---|---|
Age, years | |||
< 60 | 79(36.1%) | 40(36.0%) | 39(36.1%) |
≥ 60 | 140(63.9%) | 71(64.0%) | 69(63.9%) |
Race | |||
White | 180(82.2%) | 92(82.9%) | 88(81.5%) |
Black | 26(11.9%) | 14(12.6%) | 12(11.1%) |
Others | 12(5.5%) | 4(3.6%) | 8(7.4%) |
Unknown | 1(0.5%) | 1(0.9%) | 0(0.0%) |
Sex | |||
Female | 60(27.4%) | 32(28.8%) | 28(25.9%) |
Male | 159(72.6%) | 79(71.2%) | 80(74.1%) |
Marital status | |||
Single | 37(16.9%) | 18(16.2%) | 19(17.6%) |
Married | 129(58.9%) | 68(61.3%) | 61(56.5%) |
SDW | 43(19.6%) | 20(18.0%) | 23(21.3%) |
Unknown | 10(4.6%) | 5(4.5%) | 5(4.6%) |
Year of diagnosis | |||
2004–2009 | 113(51.6%) | 54(48.6%) | 59(54.6%) |
2010–2015 | 106(48.4%) | 57(51.4%) | 49(45.4%) |
Tumor size, cm | |||
< 4.0 | 45(20.5%) | 27(24.3%) | 18(16.7%) |
≥ 4.0 | 60(27.4%) | 27(24.3%) | 33(30.6%) |
Unknown | 114(52.1%) | 57(51.4%) | 57(52.8%) |
Primary site | |||
Trigone of bladder | 16(7.3%) | 9(8.1%) | 7(6.5%) |
Dome of bladder | 18(8.2%) | 10(9.0%) | 8(7.4%) |
Lateral wall of bladder | 26(11.9%) | 12(10.8%) | 14(13.0%) |
Anterior wall of bladder | 5(2.3%) | 2(1.8%) | 3(2.8%) |
Posterior wall of bladder | 13(5.9%) | 7(6.3%) | 6(5.6%) |
Bladder neck | 5(2.3%) | 3(2.7%) | 2(1.9%) |
Ureteric orifice | 2(0.9%) | 2(1.8%) | 0(0.0%) |
Urachus | 8(3.7%) | 5(4.5%) | 3(2.8%) |
Overlapping lesion of bladder | 32(14.6%) | 19(17.1%) | 13(12.0%) |
Bladder, NOS | 94(42.9%) | 42(37.8%) | 52(48.1%) |
T Stage | |||
T1 | 28(12.8%) | 15(13.5%) | 13(12.0%) |
T2 | 50(22.8%) | 31(27.9%) | 19(17.6%) |
T3 | 42(19.2%) | 21(18.9%) | 21(19.4%) |
T4 | 81(37.0%) | 38(34.2%) | 43(39.8%) |
Tis | 1(0.5%) | 0(0.0%) | 1(0.9%) |
TX | 17(7.8%) | 6(5.4%) | 11(10.2%) |
N stage | |||
N0 | 127(58.0%) | 72(64.9%) | 55(50.9%) |
N1 | 33(15.1%) | 14(12.6%) | 19(17.6%) |
N2 | 42(19.2%) | 20(18.0%) | 22(20.4%) |
N3 | 2(0.9%) | 1(0.9%) | 1(0.9%) |
NX | 15(6.8%) | 4(3.6%) | 11(10.2%) |
M stage | |||
M0 | 160(73.1%) | 82(73.9%) | 78(72.2%) |
M1 | 52(23.7%) | 24(21.6%) | 28(25.9%) |
MX | 7(3.2%) | 5(4.5%) | 2(1.9%) |
Grade | |||
II | 4(1.8%) | 2(1.8%) | 2(1.9%) |
III | 120(54.8%) | 52(46.8%) | 68(63.0%) |
IV | 52(23.7%) | 35(31.5%) | 17(15.7%) |
Unknown | 43(19.6%) | 22(19.8%) | 21(19.4%) |
Bone metastasis | |||
No | 101(96.2%) | 55(98.2%) | 46(93.9%) |
Yes | 4(3.8%) | 1(1.8%) | 3(6.1%) |
Brain metastasis | |||
No | 103(98.1%) | 55(98.2%) | 48(98.0%) |
Yes | 2(1.9%) | 1(1.8%) | 1(2.0%) |
Liver metastasis | |||
No | 103(98.1%) | 55(98.2%) | 48(98.0%) |
Yes | 2(1.9%) | 1(1.8%) | 1(2.0%) |
Lung metastasis | |||
No | 99(94.3%) | 52(92.9%) | 47(95.9%) |
Yes | 6(5.7%) | 4(7.1%) | 2(4.1%) |
Surgery | |||
None | 31(14.2%) | 13(11.7%) | 18(16.7%) |
TURB | 62(28.3%) | 35(31.5%) | 27(25.0%) |
Complete cystectomy + reconstruction | 49(22.4%) | 24(21.6%) | 25(23.1%) |
Pelvic exenteration | 42(19.2%) | 23(20.7%) | 19(17.6%) |
Others | 35(16.0%) | 16(14.4%) | 19(17.6%) |
Lymph nodes removed | |||
None | 121(55.3%) | 61(55.0%) | 60(55.6%) |
1 to 3 regional | 8(3.7%) | 7(6.3%) | 1(0.9%) |
4 or more regional | 82(37.4%) | 39(35.1%) | 43(39.8%) |
Unknown | 8(3.7%) | 4(3.6%) | 4(3.7%) |
Radiation | |||
None/Unknown | 172(78.5%) | 94(84.7%) | 78(72.2%) |
Yes | 47(21.5%) | 17(15.3%) | 30(27.8%) |
Chemotherapy | |||
None/Unknown | 119(54.3%) | 65(58.6%) | 54(50.0%) |
Yes | 100(45.7%) | 46(41.4%) | 54(50.0%) |
Surgery/Radiation sequence | |||
No radiation and/or surgery | 180(82.2%) | 98(88.3%) | 82(75.9%) |
Radiation after surgery | 36(16.4%) | 12(10.8%) | 24(22.2%) |
Radiation before and after surgery | 3(1.4%) | 1(0.9%) | 2(1.9%) |
Vital status | |||
Alive | 27(12.3%) | 14(12.6%) | 13(12.0%) |
Dead | 192(87.7%) | 97(87.4%) | 95(88.0%) |
Survival month | 13(6,39) | 14(6,41) | 12(5.25, 35.75) |